期刊
FUTURE MEDICINAL CHEMISTRY
卷 6, 期 17, 页码 1893-1907出版社
FUTURE SCI LTD
DOI: 10.4155/fmc.14.121
关键词
-
资金
- MRC
- Wellcome Trust
- CRUK
- University of Leeds Biomedical Health Research Centre (BHRC)
- MRC [G0700124] Funding Source: UKRI
- Medical Research Council [G0700124] Funding Source: researchfish
Hepatitis C virus (HCV) p7 is a virus-coded ion channel, or 'viroporin'. p7 is an essential HCV protein, promoting infectious virion production, and this process can be blocked by prototypic p7 inhibitors. However, prototype potency is weak and effects in clinical trials are unsatisfactory. Nevertheless, recent structural studies render p7 amenable to modern drug discovery, with studies supporting that effective drug-like molecules should be achievable. However, burgeoning HCV therapies clear infection in the majority of treated patients. This perspective summarizes current understanding of p7 channel function and structure, pertaining to the development of improved p7 inhibitors. We ask, 'is this too little, too late', or could p7 inhibitors play a role in the long-term management of HCV disease?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据